Landmark Clinical Study Validates Patch-Based Onera Home-Polysomnography System in One of the Largest Sleep Diagnostic Trials of the Decade
Study demonstrates comparable performance between wireless, patch-based Onera Sleep Test System and in-lab polysomnography for sleep staging and respiratory event detection.
Onera Health, a leader in transforming sleep medicine and remote monitoring, today announced the publication of a multicenter validation study of its Onera Sleep Test System (STS) in the Journal of Clinical Sleep Medicine, the official journal of the American Academy of Sleep Medicine. The study demonstrated that the patch-based Onera STS home-polysomnography (hPSG) performs comparably to gold-standard in-lab polysomnography (PSG) for both sleep staging and respiratory event detection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113111691/en/
A woman is conducting a sleep test (polysomnography) using the patch-based Onera STS hPSG system. (Photo: Business Wire)
The international multicenter study was managed by an independent Clinical Research Organization and involved the analysis of 206 participants across seven clinical sites in Germany and a US-based core laboratory at Johns Hopkins University. The study found high concordance between the Onera STS and traditional PSG across essential sleep variables and key respiratory parameters, as well as substantial epoch-by-epoch agreement in sleep staging and comparable inter-scorer reliability between the two systems, which is essential for physicians to make accurate diagnoses and treatment decisions in sleep medicine.
"Our rigorous multicenter validation study provides robust evidence that the Onera Sleep Test System performs comparably to traditional in-lab polysomnography for sleep staging and respiratory event detection," said Dr. Christian Viniol, MD, Ph. D, lead author and Head of Sleep Medicine at University Hospital Marburg, Germany. "This validation is crucial as we face increasing demand for sleep studies alongside increasing resource constraints. The proven accuracy of Onera’s product will significantly improve access to comprehensive sleep diagnostics, potentially transforming our approach to diagnosing and treating sleep disorders on a larger scale."
"We are thrilled with the successful completion of this comprehensive validation study," said Ruben de Francisco, Founder and CEO of Onera Health. "This validation is a critical milestone in our mission to make the gold-standard sleep test, polysomnography or PSG, available at the patient’s home. The results clearly demonstrate that our innovative, patch-based technology can deliver the level of accuracy needed for a comprehensive hPSG sleep test, with an accuracy that is equivalent to that of traditional in-lab PSG."
"These results represent an important milestone in our journey toward more accessible and personalized sleep medicine. The Onera technology enables high-quality sleep assessment in the patient's natural environment, opening new possibilities for longitudinal monitoring and improved assessment of treatment outcomes. This capability may fundamentally transform the future of sleep disorder diagnosis and treatment evaluation in the future," added Dr. David P. White, Professor of Medicine, Part Time at Harvard Medical School, Boston, United States, and Member of the Medical Advisory Board at Onera Health.
The wireless, patch-based Onera STS hPSG addresses critical challenges in sleep medicine by providing a viable alternative to traditional in-lab polysomnography. Its comparable performance in sleep staging and respiratory event detection, coupled with simplified application, significantly increases access to high-quality, comprehensive sleep assessments.
This landmark validation study is part of Onera Health's comprehensive clinical evidence generation program, demonstrating the commitment to rigorous scientific validation of Onera’s technology. Additional studies are currently ongoing across multiple centers and healthcare settings, which will further validate the clinical utility and real-world impact of Onera’s home Polysomnography solution. This evidence generation strategy reflects Onera’s dedication to advancing sleep medicine through high-quality clinical research.
The study, entitled 'Clinical validation of a wireless patch-based polysomnography system', is published in the Journal of Clinical Sleep Medicine and can be accessed online at https://jcsm.aasm.org/doi/10.5664/jcsm.11524.
About Onera
Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the U.S. For more information, go to onerahealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113111691/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processesto Enhance Efficiency and Improve Cell Quality10.2.2025 06:00:00 CET | Press release
PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary T-cell(*1) expansion culture processes that will seek to accelerate the manufacturing of cell and gene therapy (CGT) products. This joint initiative will integrate “LiCellGrowTM(*2), PHC’s cell expansion system under development, with CCRM’s deep knowledge of regenerative medicine and biomanufacturing to establish new culture processes to improve cell culture efficiency and quality for CGTs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250209611769/en/ *For research purposes only. Anticipated visual image of LiCellGrow. All features subject to change. (Graphic: Business Wire) Primary T-cells are used in process development and manufacturing for CGTs, such as in CAR-T cell therapy.(*3) However, primary T-cells derived directly from patients often exhibit significant variability in growth rates and quality, ma
NTT DATA Unveils Global Insights on GenAI Adoption in Banking: Divergent Strategies for Boosting Productivity vs. Cutting Costs10.2.2025 05:00:00 CET | Press release
Research from NTT DATA finds that as GenAI adoption rises, new pressures on return of investment are at the forefront of the challenges facing the banking industry. NTT DATA, a global digital business and IT services leader, has today launched a new global research report uncovering the use of generative AI (GenAI) in the banking sector worldwide. The report, titled “Intelligent banking in the Age of AI,” has found that despite the growing adoption of GenAI technology in the banking industry, banks and financial institutions are split when it comes to outcome-based strategies – only half of banks (50%) see it as a tool for improving productivity and efficiency. Similarly, half (49%) believe it can be used for reducing operational IT spend. Transforming Banking Through GenAI GenAI is more disruptive than any previous advance in banking technology. It is less a question of if, but when banks embrace this technology, due to its transformative ability to embed intelligence at every layer o
Revolutionizing Air Compressor Operation: ELGi Unveils Ground-breaking “STABILISOR” Technology10.2.2025 04:30:00 CET | Press release
Setting New Standards in Compressed Air Reliability, Energy Costs, and Variable Flow In a significant leap forward for industrial air compression, Elgi Equipments (BSE: 522074; NSE: ELGIEQUIP), one of the world's leading air-compressor manufacturers with over 64 years of compressed air excellence, today announced the introduction of its pioneering compressed air stabilization technology. Designed to revolutionize the way compressors operate in plants with dynamic air demand, the STABILISOR system aims to address the longstanding challenges of unstable compressor performance, inefficiency, and excessive wear caused by frequent load/unload cycles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204651563/en/ Patented Compressed Air Stabilization Technology (Graphic: Elgi Equipments) In industrial settings, the gap between compressor capacity and plant air demand is inherently dynamic. This variability leads to frequent cut-i
Andersen Global tilføjer større bredde til sit fodaftryk i Europa med Allyum i Belgien8.2.2025 14:17:00 CET | Pressemeddelelse
Andersen Global styrker sin platform i Europa gennem en samarbejdsaftale med Allyum, et førende Mergers & Acquisitions (M&A) firma i Belgien, hvilket betyder en endnu bredere skattemæssig og juridisk platform i regionen. Fra stiftelsen i 2004 har administrerende direktør Raphaël Abou, Allyum, specialiseret sig i omfattende finansielle tjenester til mid-cap virksomheder med et specifikt fokus på styring fra start til slut af transaktioner på salgssiden. Firmaet er eksperter inden for fusioner og opkøb, private investeringer, børsnoteringer, corporate venturing, aktionæromstrukturering samt finansiel analyse og planlægning. "I løbet af det seneste årti har vi hjulpet hundredvis af virksomheder med at foretage deres transaktioner og udviklet fremragende relationer med investeringsfondene i vores region," siger Raphaël. "Vores samarbejde med Andersen Global bliver en spændende mulighed for at anvende vores omfattende tilgang til finansiel rådgivning gennem den bedste globale platform." "Vi
Duravant to Acquire Pattyn, Provider of Packaging Automation Systems for Bulk and Industrial Applications7.2.2025 15:00:00 CET | Press release
Automation solutions leader Duravant has signed a definitive agreement to acquire Pattyn. Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced today that it has entered into a definitive agreement to acquire the Pattyn Group BV (‘Pattyn”), a designer and manufacturer of automation systems specializing in B2B packaging. Pattyn is recognized as the premier leader for delivering comprehensive automation solutions and value-added services for bag-in-box packaging applications. Headquartered in Bruges, Belgium, Pattyn has over 70 years of expertise in machinery design and turnkey systems for counting, weighing, filling, and packing technologies for food, ingredients, and various non-food sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207117623/en/ “We are extremely excited to partner with Pattyn,” said Mike
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom